GlassScriptPhysician profile
Pratap Balusu
NPI 1083607519
$2,671.98
in general payments reported to CMS, 2019-2025
35 companies · $39.95 in 2025
The $39.95 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $304 · 2021: $1,031 · 2022: $343 · 2023: $330 · 2024: $143 · 2025: $39.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $447.96 | 2019-2023 | Farxiga |
| Boston Scientific Corporation | $222.88 | 2021-2023 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.49 | 2020-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $163.09 | 2019-2021 | |
| Lilly USA, LLC | $160.29 | 2021-2024 | Mounjaro |
| Pfizer INC. | $148.95 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $145.44 | 2019-2023 | |
| Alkermes, INC. | $136.80 | 2020-2021 | |
| Abbvie INC. | $106.88 | 2021-2023 | Ubrelvy, Viberzi, Linzess |
| Ethicon INC. | $106.26 | 2021 | |
| Novo Nordisk INC | $103.72 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $102.58 | 2024 | Ultomiris |
| Portola Pharmaceuticals, LLC | $74.67 | 2019 | |
| Merck Sharp & Dohme LLC | $74.37 | 2020-2021 | |
| Zealand Pharma US, INC. | $49.15 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $46.77 | 2021-2022 | |
| Dexcom, INC. | $39.53 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $33.71 | 2021 | |
| Allergan, INC. | $31.23 | 2019 | |
| Lifescan, INC. | $29.10 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.54 | 2022-2024 | Lifevest |
| Biogen, INC. | $27.74 | 2021 | |
| Amgen INC. | $25.39 | 2021-2023 | Repatha, Otezla |
| Ibsa Pharma INC. | $23.72 | 2020 | |
| Inspire Medical Systems, INC. | $21.35 | 2025 | Inspire |
| Corcept Therapeutics | $20.37 | 2023 | Korlym |
| Indivior INC. | $19.67 | 2020 | |
| Exact Sciences Corporation | $18.60 | 2025 | The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $17.38 | 2022 | |
| Esperion Therapeutics, INC. | $15.69 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $15.23 | 2022 | |
| Daiichi Sankyo INC. | $13.15 | 2021 | |
| Bausch Health US, LLC | $13.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.73 | 2021 | |
| Medtronic Vascular, INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pratap Balusu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.